Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.
Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...
Hosted on MSN
Simulations Plus maintains $79M–$82M revenue guidance for 2026 while accelerating AI integration
Shawn O'Connor, Chief Executive Officer, stated that "we delivered on the first quarter top line guidance we communicated in December, with revenue decreasing 3% as expected. Adjusted EBITDA was $3.5 ...
Hosted on MSN
Simulations Plus lowers FY25 revenue guidance to $76M–$80M amid services slowdown and $77.2M impairment charge
CEO Shawn M. O'Connor reported, "Third quarter revenue came in slightly above our preliminary range communicated in June. Final results showed revenue growth of 10% to $20.4 million, including a $2.4 ...
Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...
Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementationRESEARCH TRIANGLE PARK, N.C.--(BUSINESS ...
Its full-year fiscal 2025 featured a double-digit revenue increase. As for the fourth quarter, its performance was mixed. Simulations Plus (NASDAQ: SLP) was a popular niche stock on the exchange on ...
Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...
Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results